STOCK TITAN
  1. Home
  2. News
  3. LLY

Lilly(Eli) & Co - LLY STOCK NEWS

Welcome to our dedicated news page for Lilly(Eli) & Co (Ticker: LLY), a resource for investors and traders seeking the latest updates and insights on Lilly(Eli) & Co.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Lilly(Eli) & Co's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Lilly(Eli) & Co's position in the market.

News
Tirzepatide reduced sleep apnea severity by up to nearly two-thirds in adults with obstructive sleep apnea (OSA) and obesity
Rhea-AI Summary
Tirzepatide, a drug, showed promising results in reducing sleep apnea severity by up to nearly two-thirds in adults with obstructive sleep apnea (OSA) and obesity. The mean apnea-hypopnea index reduction reached up to 63%, indicating potential benefits for patients suffering from this condition.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.54%
Tags
none
-
News
Lilly Confirms Date and Conference Call for First-Quarter 2024 Financial Results Announcement
Rhea-AI Summary
Eli Lilly and Company (NYSE: LLY) will announce its first-quarter 2024 financial results on April 30, 2024, followed by a conference call to discuss the company's financial performance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.54%
Tags
earnings
-
News
More than two-thirds of people with atopic dermatitis and skin of color experienced skin improvement in a first-of-its-kind lebrikizumab study
Rhea-AI Summary
Eli Lilly and Company announces positive results from a Phase 3 study of lebrikizumab for people with skin of color and moderate-to-severe atopic dermatitis. The study shows improvement in skin clearance and itch relief, with significant efficacy in patients of various skin tones. Lebrikizumab demonstrates potential as a first-line biologic treatment, addressing the unmet needs of underserved populations. The study includes diverse patient groups, with 68% experiencing a 75% improvement in disease severity, 46% achieving a 90% improvement, and 39% attaining clear or almost clear skin. The results are presented at the American Academy of Dermatology Annual Meeting, highlighting Lilly's commitment to health equity in dermatology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.64%
Tags
none
News
U.S. Food and Drug Administration to Convene Advisory Committee Meeting to Discuss the TRAILBLAZER-ALZ 2 Study of Donanemab
Rhea-AI Summary
Eli Lilly and Company announces FDA advisory committee meeting to discuss Phase 3 trial of donanemab for Alzheimer's disease, delaying expected FDA action in 2024. The trial shows promising results but raises safety concerns.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.31%
Tags
none
-
News
Lilly's Newest Phase of Get Better Campaign Challenges Misperceptions About Obesity Care
Rhea-AI Summary
Eli Lilly and Company launches new films as part of its Get Better campaign, focusing on obesity and the appropriate use of anti-obesity medications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.05%
Tags
none
-
News
Lilly Announces Details of Presentations at 2024 American Association for Cancer Research (AACR) Annual Meeting
Rhea-AI Summary
Eli Lilly and Company announces preclinical data for agents targeting Nectin-4, KRAS G12D, and BRM (SMARCA2) to be presented at AACR Annual Meeting. New data includes a monoclonal anti-Nectin-4 antibody, a KRAS G12D inhibitor, and a BRM (SMARCA2) inhibitor. IND applications planned for all three programs in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.28%
Tags
none
News
Lilly to Participate in Cowen's 44th Annual Health Care Conference
Rhea-AI Summary
Eli Lilly and Company (LLY) will participate in Cowen's 44th Annual Health Care Conference on March 6, 2024. Anat Ashkenazi, CFO, will engage in a fireside chat at 9:10 a.m. ET. The event will be live webcasted on Lilly's Investor website, with a replay available for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.38%
Tags
conferences
-
News
Philip Johnson to Retire as Lilly Treasurer
Rhea-AI Summary
Eli Lilly and Company (NYSE:LLY) announces the retirement of Philip Johnson, group vice president and treasurer, after 28 years of service. Johnson's impactful leadership in finance, business operations, and investor relations is highlighted, with his successor to be named later.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.61%
Tags
none
-
News
Lilly Reports Strong Fourth-Quarter 2023 Financial Results and Provides 2024 Guidance
Rhea-AI Summary
Eli Lilly and Company (LLY) announced a 28% increase in revenue in Q4 2023, with a significant growth in New Products and Growth Products revenue. The company also achieved pipeline progress, FDA approvals, and completed acquisitions, issuing a 2024 guidance of $40.4 billion to $41.6 billion in revenue.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.17%
Tags
earnings
News
Johna Norton to Retire as Lilly Executive Vice President of Global Quality
Rhea-AI Summary
Eli Lilly and Company (NYSE: LLY) announced the retirement of Johna Norton, executive vice president of Global Quality, after 34 years of service. An internal and external search is underway for her successor. Norton has made significant contributions to the company's quality standards, manufacturing processes, and team development. She has been instrumental in the successful transition of new molecules from development to manufacturing and the implementation of continuous manufacturing processes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.96%
Tags
none
Stock LLY logo
Lilly(Eli) & Co

NYSE:LLY

LLY Rankings

#10 Ranked by Market Cap
#348 Ranked by Stock Gains
#1933 Ranked by Dividends

LLY Stock Data

714.63B
897.86M
0.16%
84.31%
0.57%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Indianapolis

About LLY

Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by, and named after, Colonel Eli Lilly, a pharmaceutical chemist and veteran of the American Civil War.